Movantik

Chemical Namenaloxegol
Dosage FormTablet (oral; 12.5 mg, 25 mg)
Drug ClassOpioid antagonists
SystemDigestive
CompanyRedHill Biopharma
Approval Year2014

Indication

  • For the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation.
Last updated on 11/14/2022

More on this drug: Clinical Trials

Document TitleYearSource
Movantik (naloxegol) Prescribing Information.2020RedHill Biopharma Inc., Raleigh, NC